Literature DB >> 2302981

Complement levels in patients with hepatic dysfunction.

R T Ellison1, C R Horsburgh, J Curd.   

Abstract

Total hemolytic complement activity and serum complement protein concentrations were compared in 17 hospitalized patients with normal hepatic function and 16 patients with liver disease due to alcohol (15 patients) or acetaminophen toxicity (one patient). In contrast to the control patients, individuals with hepatic dysfunction had decreased total CH50 levels and low concentrations of total C3, C4, C5, factor B, and the regulatory proteins factor I and beta-1H. These patients also had increased C4d/C4 ratios, indicating classical pathway activation. The level of complement deficiency appears to correlate with either prolongation of the prothrombin time or depression of serum albumin concentration. These results indicate that patients with hepatic disease have severe complement depletion that is probably multifactorial in origin. This impairment in complement function will contribute to the impaired antibacterial host defense of the patient with chronic hepatic disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2302981     DOI: 10.1007/bf01536768

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  B. coli septicemia in Laennec's cirrhosis of the liver.

Authors:  R L WHIPPLE; J F HARRIS
Journal:  Ann Intern Med       Date:  1950-08       Impact factor: 25.391

2.  Acute hepatitis: significance of changes in complement components.

Authors:  J A Charlesworth; S Lawrence; P A Worsdall; L P Roy; C R Boughton
Journal:  Clin Exp Immunol       Date:  1977-06       Impact factor: 4.330

3.  Complement and liver cell function in 53 patients with liver disease.

Authors:  O Kourilsky; C Leroy; A P Peltier
Journal:  Am J Med       Date:  1973-12       Impact factor: 4.965

Review 4.  Biosynthesis of complement.

Authors:  H R Colten
Journal:  Adv Immunol       Date:  1976       Impact factor: 3.543

5.  Immune complexes in acute and chronic liver disease.

Authors:  H C Thomas; D De Villiers; B Potter; H Hodgson; S Jain; D P Jewell; S Sherlock
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

6.  Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage.

Authors:  B G Gazzard; B Portmann; I M Murray-Lyon; R Williams
Journal:  Q J Med       Date:  1975-10

7.  Clinical features and an epidemiological study of Vibrio vulnificus infections.

Authors:  C O Tacket; F Brenner; P A Blake
Journal:  J Infect Dis       Date:  1984-04       Impact factor: 5.226

8.  Complement biosynthesis by the human hepatoma-derived cell line HepG2.

Authors:  K M Morris; D P Aden; B B Knowles; H R Colten
Journal:  J Clin Invest       Date:  1982-10       Impact factor: 14.808

9.  A simple method for determining polymeric IgA-containing immune complexes.

Authors:  J Sancho; J Egido; E González
Journal:  J Immunol Methods       Date:  1983-06-10       Impact factor: 2.303

10.  Bacterial and fungal infection in children with fulminant hepatic failure: possible role of opsonisation and complement deficiency.

Authors:  V F Larcher; R J Wyke; A P Mowat; R Williams
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

View more
  9 in total

Review 1.  Extracorporeal perfusion for the treatment of acute liver failure.

Authors:  H B Stockmann; C A Hiemstra; R L Marquet; J N IJzermans
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

2.  Complement activation in acetaminophen-induced liver injury in mice.

Authors:  Rohit Singhal; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2012-02-07       Impact factor: 4.030

3.  Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality.

Authors:  C Homann; K Varming; K Høgåsen; T E Mollnes; N Graudal; A C Thomsen; P Garred
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

Review 4.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

5.  Low serum levels of alpha-interferon, gamma-interferon, and interleukin-2 in alcoholic cirrhosis.

Authors:  M M Vicente-Gutiérrez; A Diez Ruiz; B Gil Extremera; J M Bermúdez García; F Gutiérrez Gea
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

6.  Complement profile in primary biliary cirrhosis.

Authors:  M Schlesinger; C Benbassat; Y Shoenfeld
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 7.  Pig Liver Xenotransplantation: A Review of Progress Toward the Clinic.

Authors:  David K C Cooper; Ke-Feng Dou; Kai-Shan Tao; Zhao-Xu Yang; A Joseph Tector; Burcin Ekser
Journal:  Transplantation       Date:  2016-10       Impact factor: 4.939

8.  Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions.

Authors:  Yuichi Miyashima; Yuichi Honma; Koichiro Miyagawa; Shinji Oe; Michio Senju; Michihiko Shibata; Masaaki Hiura; Shintaro Abe; Masaru Harada
Journal:  Intern Med       Date:  2016-12-15       Impact factor: 1.271

9.  Proteomic study of advanced cirrhosis based on HCV to reveal potential biomarkers.

Authors:  Akram Safaei; Afsaneh Arefi Oskouie; Seyed Reza Mohebbi; Zahra Razaghi; Naser Nejadi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.